|Toxiciy Grade:||5||City/State/Province:||Orange, CA|
|Treatments:||Hormone||Hospital:||University of California Irvine Medical Center|
This study involved postmenopausal women with previously untreated metastatic breast cancer who were divided into two separate treatment groups. Group A consisted of 345 patients with a median age of 65 years. Group B had 349 patients with a median age of 65 years.
Patients in group A were treated with the hormone therapy agent anastrozole, which inhibits a protein called aromatase and interferes with tumor growth.
Patients in group B were treated with anastrozole and the hormone therapy fulvestrant which inhibits the estrogen receptor to interfere with tumor cell growth.
The most severe toxic effects in group A were of grade 4 and included blood clots, joint pain, thrombocytopenia, and shortness of breath.
There were three treatment-related deaths in group B due to blood clots and heart disorders. Grade 3 flu-like symptoms and joint pain were also reported.
The median overall survival for groups A and B was 41.3 and 47.7 months, respectively.
This study was partially supported by AstraZeneca.
Correspondence: Dr. Rita S. Mehta; email: email@example.com